» Articles » PMID: 2110478

A Comparison of Strategies to Stabilize Immunoglobulin Fv-fragments

Overview
Journal Biochemistry
Specialty Biochemistry
Date 1990 Feb 13
PMID 2110478
Citations 78
Authors
Affiliations
Soon will be listed here.
Abstract

Fv-Fragments of antibodies may dissociate at low protein concentrations and are too unstable for many applications at physiological temperatures. To stabilize Fv-fragments against dissociation, we have tested and compared three different strategies on the Fv-fragment of the well-characterized phosphocholine binding antibody McPC603 expressed and secreted in Escherichia coli: chemical cross-linking of the variable domains, introduction of an intermolecular disulfide bond, and construction of a peptide linker to produce a "single-chain" Fv-fragment. All the linked fragments show hapten affinities nearly identical with that of the whole antibody independent of protein concentration and are significantly (up to 60-fold) stabilized against irreversible thermal denaturation. All genetically engineered linked Fv-fragments can be obtained in native conformation in E. coli. The reported strategies for generating Fv-fragments with improved physicochemical properties may extend their usefulness in biotechnology as well as in therapeutic and diagnostic applications.

Citing Articles

Targeted Therapy with a Novel Superantigen-based Fusion Protein Against Interleukin-13 Receptor α2-overexpressing Tumor Cells: An In-silico Study.

Gholipour Z, Fooladi A, Parivar K Iran J Pathol. 2024; 19(2):193-204.

PMID: 39118800 PMC: 11304462. DOI: 10.30699/IJP.2024.2014231.3200.


Immunotherapy of Hematological Malignancies of Human B-Cell Origin with CD19 CAR T Lymphocytes.

Khvorost D, Kendall B, Jazirehi A Cells. 2024; 13(8.

PMID: 38667277 PMC: 11048755. DOI: 10.3390/cells13080662.


Advanced strategies in improving the immunotherapeutic effect of CAR-T cell therapy.

Wang M, Jia L, Dai X, Zhang X Mol Oncol. 2024; 18(8):1821-1848.

PMID: 38456710 PMC: 11306536. DOI: 10.1002/1878-0261.13621.


Serum immunoglobulin or albumin binding single-domain antibodies that enable tailored half-life extension of biologics in multiple animal species.

Harmsen M, Ackerschott B, de Smit H Front Immunol. 2024; 15:1346328.

PMID: 38352869 PMC: 10862077. DOI: 10.3389/fimmu.2024.1346328.


TRYBE®: an Fc-free antibody format with three monovalent targeting arms engineered for long in vivo half-life.

Dave E, Durrant O, Dhami N, Compson J, Broadbridge J, Archer S MAbs. 2023; 15(1):2160229.

PMID: 36788124 PMC: 9937000. DOI: 10.1080/19420862.2022.2160229.